Regeneron’s POTS antibody curbs heart rate spikes, teeing up Phase 3 trial
Regeneron's Phase 2 trial for baloncibart (REGN7544) in POTS patients showed significant heart rate reduction at day 8, with the 450-mg dose maintaining benefits at day 29. The company plans to initiate Phase 3 trials in early 2025. According to Regeneron, the drug was generally well-tolerated, and improvements in physical functioning were observed in the higher dose group.
How this was made
The 30-second read
Why it matters
The data provides a clear efficacy signal and a path to Phase 3, potentially adding a new revenue stream.
Market read
First‑report Phase 2 data for a novel autonomic‑disorder therapy; may influence Regeneron's stock and biotech sentiment.
What to watch
Regeneron's existing pipeline and cash position may limit the upside from a single indication.
Background
Regeneron disclosed Phase 2 results for baloncibart (REGN7544) in POTS, a disorder with no approved treatments.
Ticker impact
Regeneron reported positive Phase 2 data for its POTS antibody baloncibart, showing an 11.4‑bpm heart‑rate reduction and plans for a Phase 3 trial.
likely upward pressure as investors price in potential Phase 3 success and a new therapeutic market.
Phase 2 results exceed placebo and demonstrate durable effect, a material catalyst for a biotech with a sizable pipeline.
Market effects
strengthens the biotech/rare‑disease therapeutic space and may spur interest in other autonomic‑disorder programs.
U.S. biotech sector could see modest uplift.
limited to investors tracking clinical‑trial pipelines.
Counterpoint
If Phase 3 fails or regulatory hurdles arise, the stock could face a sharp correction.
Key entities
- companyRegeneron Pharmaceuticals
US biotech developing the POTS antibody.
